MX2011008963A - Profarmacos portadores de interferon alfa. - Google Patents

Profarmacos portadores de interferon alfa.

Info

Publication number
MX2011008963A
MX2011008963A MX2011008963A MX2011008963A MX2011008963A MX 2011008963 A MX2011008963 A MX 2011008963A MX 2011008963 A MX2011008963 A MX 2011008963A MX 2011008963 A MX2011008963 A MX 2011008963A MX 2011008963 A MX2011008963 A MX 2011008963A
Authority
MX
Mexico
Prior art keywords
interferon alpha
carrier prodrugs
pharmaceutical composition
prodrug
prodrugs
Prior art date
Application number
MX2011008963A
Other languages
English (en)
Inventor
Harald Rau
Silvia Kaden-Vagt
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of MX2011008963A publication Critical patent/MX2011008963A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un profármaco enlazado al portador polimérico soluble en agua del interferón alfa, en donde el profármaco es capaz de liberar el interferón alta libre, en donde la vida media de liberación bajo las condiciones fisiológicas es de al menos 4 días. La invención se refiere además a los profármacos para la composición farmacéutica y su uso para el tratamiento, control, retardo o prevención de una condición que puede beneficiarse del tratamiento con el interferón alfa, tal como la hepatitis C.
MX2011008963A 2009-03-05 2010-03-04 Profarmacos portadores de interferon alfa. MX2011008963A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154449 2009-03-05
EP09180477 2009-12-22
PCT/EP2010/052745 WO2010100220A1 (en) 2009-03-05 2010-03-04 Interferon alpha carrier prodrugs

Publications (1)

Publication Number Publication Date
MX2011008963A true MX2011008963A (es) 2012-02-01

Family

ID=42041523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008963A MX2011008963A (es) 2009-03-05 2010-03-04 Profarmacos portadores de interferon alfa.

Country Status (10)

Country Link
US (1) US20120058084A1 (es)
EP (1) EP2403537A1 (es)
JP (1) JP2012519666A (es)
CN (1) CN102413843A (es)
AU (1) AU2010220324A1 (es)
BR (1) BRPI1013227A2 (es)
CA (1) CA2753001A1 (es)
MX (1) MX2011008963A (es)
RU (1) RU2011140219A (es)
WO (1) WO2010100220A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482347B (zh) * 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
RU2558847C9 (ru) 2009-10-29 2016-07-20 Асцендис Фарма Ас Стерилизация биоразлагаемых гидрогелей
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CA2808748C (en) 2010-09-14 2018-09-11 Roberto Falkenstein Method for purifying pegylated erythropoietin
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
CA2885169C (en) 2012-10-11 2021-06-22 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812507A1 (de) 1988-04-15 1989-10-26 Sachsenwerk Ag Schaltfeld fuer eine gekapselte mittelspannungs-schaltanlage
DE19510438A1 (de) 1995-03-22 1996-09-26 Basf Ag Verfahren zur Herstellung von 1,4-Butandiol und Tetrahydrofuran aus Furan
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
CA2521784C (en) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker

Also Published As

Publication number Publication date
WO2010100220A1 (en) 2010-09-10
EP2403537A1 (en) 2012-01-11
US20120058084A1 (en) 2012-03-08
AU2010220324A1 (en) 2011-09-01
JP2012519666A (ja) 2012-08-30
BRPI1013227A2 (pt) 2016-03-29
RU2011140219A (ru) 2013-04-10
CA2753001A1 (en) 2010-09-10
CN102413843A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
MX2011008963A (es) Profarmacos portadores de interferon alfa.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
MX2016009449A (es) Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
NZ594755A (en) Cyclosporin analogues for preventing or treating hepatitis c infection
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
IN2012DN00869A (es)
MX2012001244A (es) Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta.
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
BR112012031288A2 (pt) composições
MX2010000965A (es) Productos de farmaco de interferon de liberacion controlada y tratamiento de la infeccion del virus de hepatitis c usando los mismos.
IN2012DN02624A (es)
EP2438923A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS
HK1141980A1 (en) Use of carrageenan for treating rhinovirus infections
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
TW200719903A (en) Compositions for the treatment of neoplasms
ATE551319T1 (de) Sgk1-inhibitoren zur prophylaxe und/oder therapie von viralen erkrankungen und/oder karzinomen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal